Alibaba Health's Strategic Investment in LinkDoc Reveals Its Ambitious Blueprint in Serious Healthcare

The development of the internet healthcare industry has long been mired in controversy.

The underlying reason is that the industry’s business model remains relatively homogeneous. An analysis of the revenue structures of leading companies reveals that pharmaceutical e-commerce is currently the primary source of revenue and profits for major internet healthcare companies.

Taking AliHealth as an example, its interim financial report for fiscal year 2021 showed that revenues from its self-operated pharmaceutical business and pharmaceutical e-commerce platform business were RMB 6.036 billion and RMB 925 million, respectively, totaling RMB 6.961 billion, which accounted for 97.2% of total revenue. The self-operated pharmaceutical business remains the primary component of its revenue. This trend is also evident among other leading internet healthcare companies, such as JD Health and Ping An Good Doctor.

Thus, “e-commerce players rely on drug sales, while non-e-commerce players depend on financing for lifeline support” has become a common assessment of the internet healthcare industry among many observers.

Is this really the case? Half of it is correct. From the current perspective, pharmaceutical e-commerce is indeed a significant revenue source for internet healthcare companies. However, the other half is inaccurate in that industry pioneers such as AliHealth are gradually expanding into digital healthcare and health technology sectors, aiming to become key participants and drivers of the broader health ecosystem.

Therefore, when analyzing an industry and its enterprises, one should not focus solely on the performance reflected in current financial data, capital market effects, or emerging terminology and concepts. Greater attention should be paid to the evolution of the underlying business logic behind every action taken by the industry and enterprises, as well as their future forecasts and the resources and practices aligned with these projections.

Recently, LinkDoc, a unicorn in the medical big data sector, announced that it had received strategic investment from AliHealth. The two parties will jointly build a patient-centric, technology-driven service platform covering the entire disease journey for cancer patients in China. They will actively explore innovative online service models for oncology-specific pharmaceuticals and establish an integrated online-offline oncology care network, thereby providing cancer patients with high-quality healthcare services spanning the full disease continuum, from clinical care to medication.

This strategic investment in LinkDoc Technology represents both AliHealth’s new expansion into the field of critical illnesses and its commitment to leveraging innovative internet technologies to support serious medical care.

It is evident that as AliHealth expands from pharmaceutical retail and related businesses into the realm of serious medical care, a new strategic landscape—long hidden beneath the surface—is gradually coming to light.

Five months ago, AliHealth’s interim financial report for fiscal year 2021 revealed that the company generated RMB 7.16 billion in revenue and achieved a net profit of RMB 280 million over the six-month period. This marked the first time the internet healthcare giant has turned a profit since its establishment six years ago.

An analysis of the financial report reveals that, in addition to the rapidly growing proprietary pharmaceutical business, both the healthcare services and digital health segments experienced significant upward momentum, with revenue growth rates reaching 43.3% and 30.3%, respectively.

Behind these two business lines lies AliHealth’s growing endeavor to penetrate various segments of the healthcare industry, ranging from smart hospitals and medical AI to the use of traceability codes to facilitate new drug R&D, with a strategic layout spanning both B-end and C-end markets. Notably, a clear thread underpins these initiatives: building digital infrastructure for the healthcare sector based on cutting-edge technologies such as AI, big data, and informatization. The growth in performance of these businesses demonstrates that AliHealth has achieved considerable success in fields such as digital health.

From this perspective, the strategic investment in LinkDoc Technology, a leading enterprise in medical big data, is a significant move by AliHealth to further its deployment in the new digital healthcare infrastructure.

As a technology enterprise long committed to oncology big data and artificial intelligence, LinkDoc Technology provides comprehensive big data and AI solutions for stakeholders in the pharmaceutical and healthcare industries. Its current core businesses include real-world studies of drugs, patient health management, and patient recruitment services, with a focus on delivering solutions for major disease areas represented by cancer and rare diseases.

On the other hand, AliHealth has ventured into research, diagnosis, and treatment of major diseases, as well as genetic testing and biological vaccines, through an internet-based model. Through this strategic investment partnership, AliHealth and LinkDoc Technology will leverage their respective capabilities in the field of major diseases to connect platforms such as AliHealth’s platform, LinkDoc Internet Hospital, and Oncology Patient Service Centers, thereby providing users with precise and convenient services for critical illnesses and enhancing the level of disease treatment and care.

In other words, AliHealth aims to further advance its accumulated technological capabilities through collaboration with LinkDoc Technology, thereby unlocking new possibilities in the field of serious medical care.

Of course, many companies specializing in medical big data have emerged in recent years. Why did AliHealth specifically choose LinkDoc Technology? This necessitates a discussion of the current state of the medical big data industry.

According to the “Research Report on Market Potential Analysis and Investment Opportunities in China’s Healthcare Big Data Industry (2019–2025)” released by Zhiyan Consulting Group, although healthcare big data boasts broad application prospects—with niche scenarios such as assisted diagnosis and treatment and health management being closely related to people’s lives and demonstrating strong practical value—the industry currently still faces two major pain points.

First, the data sources are highly complex. In addition to routine laboratory tests and physician-documented medical records, it is necessary to collect data such as genetic testing results and health examination information, which poses a high barrier to entry for market participants. Second, clinical standards for computer-aided diagnosis are stringent, requiring robust causal relationships between medical data and diagnostic conclusions; this significantly tests a company’s understanding of the healthcare industry.

Addressing these two critical challenges, LinkDoc Technology provides clients with services for data structuring and data application layers. To this end, the company has assembled a team of over 1,000 professionals spanning clinical medicine, computer science, drug R&D, artificial intelligence technology, and commercialization services. It has collaborated with more than one hundred Grade A tertiary hospitals across China to build a self-developed, globally advanced medical big data processing platform and technical support system. This infrastructure enables data governance, mining, and analytical applications, delivering end-to-end medical technology solutions for major diseases to the industry. Practical outcomes demonstrate that LinkDoc Technology’s business now covers all 31 provinces, municipalities, and autonomous regions in China, having cumulatively served tens of thousands of frontline clinical physicians and millions of patients with cancer and other critical illnesses.

Let’s examine the market potential. According to data from the National Health Commission, China sees over 3.5 million new cancer cases and more than 2 million cancer-related deaths annually, underscoring a severe prevention and control situation. There is an urgent industry demand for innovative drugs and treatment regimens in oncology. Consequently, delving deeply into oncology big data holds significant promise for expanding both parties’ future market reach.

In summary, this collaboration was driven by AliHealth’s determination to leverage internet technology to support evidence-based medicine and its strategic commitment to advancing new digital healthcare infrastructure, combined with LinkDoc Technology’s boldness in continuously promoting the application of oncology big data and deeply exploring clinical scenarios.

Seizing this opportunity, AliHealth has taken a significant step forward in its plan to deploy technology and services across the entire healthcare spectrum.

How Should We Evaluate a Company? Answering this question is tantamount to addressing how we perceive a company’s growth: from a static perspective or a dynamic one.

According to McKinsey’s Three Horizons framework, Alibaba possesses a robust portfolio of core businesses in the first horizon, namely e-commerce platforms such as Taobao and Tmall. In the second horizon, which is expected to generate substantial revenue, the company holds strong positions in technology-driven financial services through Ant Group. Furthermore, in the third horizon, which focuses on future-oriented and emerging ventures, Alibaba continues to foster innovative businesses such as Alibaba Cloud and digital media.

AliHealth is also continuously evolving along this path. An analysis of AliHealth’s past initiatives and its annual financial reports reveals that the company has undergone three major transitions in its business model.

The first phase, from 2015 to 2016, saw AliHealth leverage Alibaba’s inherent strengths in e-commerce to rapidly expand into the pharmaceutical e-commerce sector, establishing both its proprietary pharmaceutical business and a pharmaceutical e-commerce platform, which gradually evolved into a health management service platform. The second phase, from 2017 to 2019, involved AliHealth utilizing Alibaba’s ecosystem resources, such as Alipay, to build an integrated online-offline internet-based tiered diagnosis and treatment system. The third phase, from 2020 to the present, has been marked by AliHealth’s in-depth layout of digital infrastructure within the healthcare industry.

As the evolutionary trajectory indicates, AliHealth is not only consolidating its established core businesses but also actively expanding outward, continuously evolving from its origins as a pharmaceutical e-commerce platform into a comprehensive healthcare technology and services enterprise with a full-spectrum layout.

Following this approach, AliHealth has established business segments including pharmaceutical e-commerce, internet healthcare, traceability code platforms, and smart healthcare, involving multiple stakeholders such as patients, hospitals, physicians, pharmaceutical companies, and insurers.

Setting aside specific business classifications, AliHealth’s operations are primarily concentrated in two areas: commercial-oriented new retail pharmaceutical businesses (including pharmaceutical e-commerce platforms, self-operated pharmaceutical e-commerce, and online-to-offline [O2O] pharmaceutical services) and technology-driven healthcare tech businesses (including internet healthcare, traceability services, and smart healthcare). These two pillars constitute the driving flywheel of AliHealth’s development, propelling its continuous “deep dive” into the blue ocean of digital healthcare infrastructure.

However, judging from AliHealth’s significant investments in recent years, pharmaceutical new retail serves as its immediate revenue driver and cash cow, while medical technology-oriented businesses represent its strategic future.

As AliHealth’s revenue and profitability continue to grow, the substantial contribution of pharmaceutical sales has become a focal point of widespread industry discussion.

In reality, compared with offline medical services, internet-based healthcare primarily focuses on online consultations and prescription refills for common and chronic diseases, as it cannot perform diagnostic tests or surgical procedures. For platforms that provide both medical services and pharmaceuticals, drugs naturally account for a significant proportion of revenue. Therefore, one should not simply judge a company’s strategic layout based on the largest component of its revenue.

Since its inception, AliHealth has been continuously advancing into the “deep-water zones” of the healthcare industry, such as smart healthcare.

In November last year, the “Future Hospital” information system, jointly developed by Alibaba and The First Affiliated Hospital, Zhejiang University School of Medicine (hereinafter referred to as “FAHZU”), was officially launched, becoming China’s first cloud-architecture-based smart hospital information system.

As a regional medical center, The First Affiliated Hospital, Zhejiang University School of Medicine (FAHZU) has undergone years of informatization development. However, with the construction of new campuses in Yuhang and Zhijiang, FAHZU is facing an explosion in data volume, rendering its legacy systems incapable of providing sufficient computational power. Furthermore, the proliferation of disparate systems across various campuses, coupled with the lack of interoperability and information integration, forces medical staff to frequently switch between multiple systems in their daily work.

To address this issue, XiNiu Medical (a key strategic initiative of AliHealth in the digital healthcare sector) undertook the development of the system. Consequently, an information system built entirely on a cloud-based architecture was established. Leveraging robust cloud computing capabilities, the system manages the massive, real-time data flows to enable centralized management and scheduling of patient information and medical resources, facilitating intelligent and efficient matching. It also supports cross-campus patient transfers, intelligent multi-campus physician scheduling, and smart appointment booking for examinations and tests across multiple campuses.

Based on this system, the First Affiliated Hospital of Zhejiang University School of Medicine has consolidated common resources from its medical information systems into multiple capability centers—including a Patient Center, Appointment Center, Medical Insurance Center, and Payment Center—thereby enhancing system interoperability, improving diagnostic, therapeutic, and operational efficiency, and facilitating patient access to care.

Furthermore, to strengthen service oversight in the pharmaceutical distribution chain, AliHealth leveraged traceability code technology to launch the first online authenticity guarantee mechanism for medication purchases during last year’s Tmall Double 11 Shopping Festival. Consumers who purchase medicines marked with the “Little Blue Heart” logo on Tmall can trace the origin of their medications by scanning the codes via Taobao or Alipay, and are also eligible for a genuine-product insurance policy that provides tenfold compensation for any counterfeit items.

Beyond its application in pharmaceutical distribution, AliHealth has extended traceability code technology to clinical trials for new drug development and non-pharmaceutical product traceability. Previously, Chinese research teams incorporated the “Ma Shang Fang Xin” (Code for Assurance) traceability system into the Ministry of Science and Technology-approved project on “Stem Cell Therapy for COVID-19,” achieving end-to-end traceability of investigational medicinal products in clinical trials for the first time. This innovation effectively ensured the integrity of trial results and accelerated the progress of clinical trials, thereby validating the transferability of AliHealth’s capabilities in building new digital healthcare infrastructure. In terms of revenue, AliHealth’s traceability and digital healthcare services generated RMB 24.7 million in the first half of fiscal year 2021. Although this figure is modest relative to its overall revenue scale, it demonstrates that AliHealth has ignited a promising spark in the field of healthcare digitalization.

AliHealth’s zero-cost strategic investment marks a critical move in its deep dive into life sciences. Henceforth, AliHealth’s journey in medical big data will no longer be confined to non-clinical data. In the pharmaceutical R&D sector, dominated by industry giants, AliHealth is gradually building its influence.

In summary, as a new growth frontier for AliHealth and a critical component of its business flywheel, medical technology-driven services have achieved significant breakthroughs. These advancements will provide substantial momentum in upcoming market validations, empowering AliHealth to lead the development of new digital healthcare infrastructure.

What Value Should Internet Giants Bring to the Industry and Society?

Internet giants, armed with vast pools of tech talent, ample capital, massive user traffic, and even dominant distribution channels, often meet with unparalleled success when initially entering a specific niche market. Leveraging these advantages, there is a public expectation that these tech behemoths will combine technology and capital to drive greater efficiency and deliver superior service experiences, thereby improving our lives.

At this juncture, AliHealth has leveraged its new retail pharmacy model to continuously optimize the integrated process of diagnosis, treatment, and medication procurement. By bolstering its strategic resources and capabilities, the company is advancing into the “deep waters” of the healthcare industry, aiming to participate in the sweeping tide of medical reform as both a collaborator and a practitioner.

It is precisely on this basis that AliHealth has demonstrated a clear strategic direction, whether through its collaboration with The First Affiliated Hospital of Zhejiang University School of Medicine to build the “Future Hospital” information system and elevate the hospital’s informatization capabilities, or through its strategic investment in LinkDoc Technology to deliver better services and experiences for cancer patients. This will provide significant momentum for AliHealth to emerge as a key disruptor in the healthcare industry.

Of course, it is important to note that the healthcare sector is a “slow industry,” requiring participants to possess ample patience, perseverance, and compassion. Only in this way can AliHealth, witnessed by the passage of time, successfully bring its vibrant medical dreams to fruition.